Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

975: LEVOFLOXACIN DRUG MONITORING IN CONTINUOUS VENOVENOUS HEMODIAFILTRATION FOR LEGIONELLA PNEUMONIA
Whitenack, Kaylee, Robinson, John A. , Schwarz, Jacob B. , Robinson, John, Ilges, Dan , Schwarz, Jacob

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102564.45586.c3 Get It

982: EXTERNAL VALIDATION OF THE FRASER EQUATION TO ESTIMATE FREE VALPROATE CONCENTRATION IN THE ICU
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Gagnon, David J. , Webb, Andrew , Rosenthal, Eric S.

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102592.08813.34 Get It

985: MODIFIED NIMODIPINE DOSE AND FUNCTIONAL OUTCOME IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE
Sacco, Alicia , Shiue, Harn

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102604.22479.db Get It

948: CARDIOVASCULAR PROFILE OF KETAMINE THERAPY FOR DEPRESSION IN ICU PATIENTS
Pareek, Aayushi , Jena, Anek , Raavi, Lekhya , Blumenfeld, Sophia G. , Jonna, Sadhana , Hanson, Abby , Siassi, Zara, Pietrzak, Katheleen A., Ojard, Michelle, Villar, Dolores, Shapiro, Anna B, Sanghavi, Devang , Isha, Shahin , Siassi, Zara, Kunze, Katie L. , Johnson, Patrick W. , Huespe, Iván , Shah, Sadia , Franco, Pablo Moreno , Edwards, Michael A.

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102456.05557.51 Get It

Corynebacterium mayonis sp. nov. isolated from a human blood culture
Mohammed, Hamidu T. , Koscianski, Christina, Berent, Taylor E. , Gordy, Garrett G. , Herren, Sebastian , Patel, Robin , Koscianski, Christina A, Herren, Sebastian C , Patel, Robin , Johnson, Stephen A.

International Journal of Systematic and Evolutionary Microbiology | January 31, 2025 | Volume: 75 | Issue: 1 | Pages: No page available

10.1099/ijsem.0.006632 | PMID 39887037 Get It

A novel Corynebacterium species, strain BD556T, isolated from blood, was identified at Mayo Clinic, Rochester, MN, USA. After failing definitive identification using MALDI-ToF MS and partial 16S rRNA gene sequencing, BD556T was characterized using a polyphasic approach, including phenotypic, biochemical and whole-genome sequencing methods. BD556T was a Gram-positive rod with clubbed ends, facultatively anaerobic, catalase-positive, oxidase-negative and non-motile. Colonies were white, opaque and non-haemolytic with halo-like edges. BD556T grew at 35 °C in room air, with CO2 and under anaerobic conditions. BD556T grew well in 0 and 6% NaCl and weakly in 10% NaCl. The genome size was 2 349 779 bp with a G+C content of 60.39%. Phylogenetic analysis using 16S rRNA gene sequence analysis, average nucleotide identity and digital DNA–DNA hybridization between the genome of BD556T and the closest type strains from the Type Strain Genome Server database yielded separation values well beyond those required for species delineation. Chemotaxonomic analyses of BD556T revealed ribose, arabinose and galactose as whole-cell sugars and an A1γ meso-diaminopimelic acid-direct peptidoglycan type. The major cellular fatty acids were C15 : 0 (21.0%), C16 : 0 (14.8%), C17 : 1 ω9c (26.2%), C17 : 0 (13.3%) and C18 : 1 ω9c (18.3%). Polar lipids included diphosphatidylglycerol, phosphatidylglycerol and unidentified glycolipids and phospholipids. BD556T also contained mycolic acids (32–36 carbons) typical of corynebacteria. The respiratory quinones were dominated by MK-8(H2) (71.2%) and MK-9(H2) (25.9%), with smaller amounts of MK-7(H2) and MK-10(H2). The results presented support the tenet that BD556T (=TSD 427T=NCTC 15078T) is a novel species for which the name Corynebacterium mayonis sp. nov. is proposed.
Immune Aging and Its Implication for Age-Related Disease Progression
Sato, Yuki

Physiology | January 31, 2025 | Volume: 40 | Issue: 4 | Pages: 363-373

10.1152/physiol.00051.2024 | PMID 39887318 Get It

As life expectancy increases globally, the prevalence and severity of age-related diseases have risen, significantly impacting patients’ quality of life and increasing dependency on the healthcare system. Age-related diseases share several pathological commonalities, and emerging evidence suggests that targeting these biological processes ameliorates multiple age-related diseases. Immune aging plays a critical role in the pathogenesis of age-related diseases, given its involvement not only in controlling infection and cancer but also in facilitating tissue homeostasis and repair. Aging causes compositional and functional changes in both innate and adaptive immune cells, thereby significantly contributing to the pathogenesis of age-related disease and systemic low-grade inflammation, termed “inflammaging.” This review article aims to describe the current understanding of immune aging and its impact on age-related diseases with particular emphasis on kidney and autoimmune diseases. In addition, this review highlights tertiary lymphoid structures (TLS) as a hallmark of immune aging, exploring their roles in inflammation, tissue damage, and potential therapeutic targeting.
ACG 2024 Presidential Speech
Leighton, Jonathan A.

American Journal of Gastroenterology | January 31, 2025 | Volume: 120 | Issue: 2 | Pages: 265-267

10.14309/ajg.0000000000003254 | PMID 39887122 Get It

Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma
O'Donnell, C. , Rutenberg, Michael, Croome, Kristopher P. , Poruk, Katherine E. , Toskich, Beau B. , Jin, Zhaohui , O'Donnell, Conor D J , Rutenberg, Michael , Croome, Kris P , Jin, Zhaohui , Majeed, Umair

Current Oncology | January 31, 2025 | Volume: 32 | Issue: 2 | Pages: 82

10.3390/curroncol32020082 | PMID 39996882 Get It

Intrahepatic cholangiocarcinoma is an aggressive malignancy with rising incidence and poor outcomes. This review examines recent advancements in locoregional therapies for unresectable intrahepatic cholangiocarcinoma, focusing on external beam radiotherapy, transarterial radioembolization (TARE), hepatic artery infusion pump (HAIP) chemotherapy, and liver transplantation. Stereotactic body radiation therapy and proton beam therapy have shown promise in achieving local control and improving survival. TARE, with personalized dosimetry, has demonstrated encouraging results in select patient populations. HAIP chemotherapy, primarily studied using floxuridine, has yielded impressive survival outcomes in phase II trials. Liver transplantation, once contraindicated, is now being reconsidered for carefully selected patients with localized disease. While these locoregional approaches show potential, randomized controlled trials comparing them to standard systemic therapy are lacking. Patient selection remains crucial, with factors such as liver function, tumor burden, and molecular profile influencing treatment decisions. Ongoing research aims to optimize treatment sequencing, explore combination strategies with systemic therapies, and refine phenotype identification and patient selection criteria. As the landscape of intrahepatic cholangiocarcinoma management evolves, a multidisciplinary approach is essential to tailor treatment strategies and improve outcomes for patients with this challenging disease.
Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
González, Raul S. , Horton, Rachel K. , Zhang, Xuchen , Graham, Rondell P. , Longacre, Teri A. , Mehrotra, Anupamjit K., Allende, Daniela , McHugh, Kelsey , Shia, Jinru , Westerhoff, Maria , Chen, Wei , Vazzano, Jennifer , Cheema, Hassam, Ma, Changqing , Mannan, Abul Ala Syed Rifat , Agostini‐Vulaj, Diana , Kazemimood, Rossana , Henn, Patrick, Kakar, Sanjay , Choi, Won‐Tak , Adeyi, Oyedele , Allende, Daniela S , McHugh, Kelsey E , Srivastava, Amitabh , Chen, Wei , Vazzano, Jennifer , Swanson, Paul E , Ma, Changqing , Mannan, Abul A S R , Chetty, Runjan , Serra, Stefano , Agostini-Vulaj, Diana , Kazemimood, Rossana , Choi, Won-Tak , Adeyi, Oyedele , Jenkins, Sarah M. , Nagtegaal, Iris D , Gonzalez, Raul S , Graham, Rondell P , Srivastava, Amitabh , Chatterjee, Deyali , Nowak, Klaudia , Kakar, Sanjay , Jenkins, Sarah M, Nagtegaal, Irıs D.

Histopathology | January 31, 2025 | Volume: 86 | Issue: 7 | Pages: 1064-1081

10.1111/his.15412 | PMID 39887413 Get It

AimsWe compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta‐analysis of cohorts and individual case series.Methods and ResultsWe identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome. ASC comprised 0.02% of colorectal cancers in the Dutch database. The median cohort patient ages at resection were 65 and 69 years (North American and Dutch cohorts, respectively), with a roughly equal male:female ratio. The squamous component represented between 5% and 95% of each tumour, with a median of 50%. Tumour‐infiltrating lymphocytes (TILs) were generally low (66%), and tumour budding was often Bd1 (64%). Most cases were pT3 (55%) or pT4 (40%), with nodal metastases in more than half (58%). Twenty‐three cases (43%) metastasized distantly, most commonly to the liver. Mismatch repair (MMR) deficiency was identified in 34% of the cases. Follow‐up was available for 48 patients; 13 (27%) had recurrent disease and 29 (60%) died. A total of 31 patients progressed, with median time to progression of 18 months. Available data for the Dutch cohort revealed largely similar findings, as did review of cases in the literature.ConclusionColorectal ASC usually presents at an advanced stage. Despite high rates of MMR deficiency and low tumour budding, TILs were generally low, and there is a high recurrence rate and poor prognosis.